Moxifloxacin in the Outpatient Treatment of Moderate Exacerbations of Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.3889/oamjms.2018.445Keywords:
Antibiotic, Bacterial infection, Chronic obstructive pulmonary disease, Clinical success, Exacerbation, Side effectsAbstract
BACKGROUND: Bacterial infections are involved in more than a half of the exacerbations of chronic obstructive pulmonary disease (COPD).
AIM: To evaluate the efficacy and safety of moxifloxacin in the outpatient treatment of moderate exacerbations of bacterial origin in the COPD patients.
METHODS: We performed a prospective, observational study including 64 COPD patients with moderate exacerbation of bacterial origin empirically treated with moxifloxacin. In 31 of them, moxifloxacin was used as an initial antibiotic (Group 1), whereas in 33 of them moxifloxacin was used after treatment failure with another antibiotic (Group 2). All patients have treated 7 days with moxifloxacin 400 mg once daily per os, and they were followed up for 20 days, with an intermediate visit at 3, 5 and 7 days at which the duration of symptoms and the side effects of the drug were evaluated.
RESULTS: We registered high clinical success rate, i.e. the complete resolution of the symptoms or their return to the baseline severity, similar in both groups (84.3% in all study subjects, 83.9% in the Group 1 and 84.8% in the Group 2). The mean time to complete resolution of the cardinal symptoms or their return to the baseline severity was 5.2 ± 1.1 days. Also, the mean time to complete resolution of the certain cardinal symptoms (increased dyspnea, increased sputum volume and increased sputum purulence) or their return to the baseline severity is given 4.9, 4.7 and 4.2 days, respectively. The incidence of adverse effects during the treatment with moxifloxacin in all study subjects was 10.9%, 9.6% in Group 1 and 12.1% in Group 2. There was no serious adverse effect that required discontinuation of the treatment. Relapse during a 20 days follow-up period was registered in 7.4% of the all study subjects with complete resolution of the cardinal symptoms or their return to the baseline severity, i.e. in two patients from both Group 1 and Group 2 (7.6% and 7.1%, respectively).
CONCLUSION: Our findings suggest high efficacy and good tolerability of moxifloxacin in the treatment of moderate COPD exacerbations of bacterial origin.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Tan WC, Bourbeau J, Aaron SD, Zhou G, Maltais F, Hernandez P, Fitzgerald JM, Marciniuk DD, Walker BL, Sin DD. Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2018; 197(5):670-3. https://doi.org/10.1164/rccm.201706-1154LE PMid:28858570
Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55:114-120. https://doi.org/10.1136/thorax.55.2.114 PMid:10639527 PMCid:PMC1745686
Miravittles M, Niederman M. Lectures in Respiratory Tract Infections: Acute Exacerbations of Chronic Bronchitis.
Ball P, Chodosh S, Grossman R, et al. Causes, epidemiology, and treatment of bronchial infections. Infect Med. 2000; 17:186-198.
Sethi S, Wrona C, Grant BJB, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 169:448-453. https://doi.org/10.1164/rccm.200308-1181OC PMid:14597486
Anthonisen NR, Menfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204. https://doi.org/10.7326/0003-4819-106-2-196 PMid:3492164
Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26:1138-1180. https://doi.org/10.1183/09031936.05.00055705 PMid:16319346
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6):932-946. https://doi.org/10.1183/09031936.04.00014304
Auwaerter PG, Barlett JG. Chronic bronchitis, Acute exacerbations. Available at: https://www. hopkinsguides.com/ (Accessed 14.08.2017).
Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002; 9:191-197. https://doi.org/10.1097/00045413-200207000-00001
Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000; 59:115-139. https://doi.org/10.2165/00003495-200059010-00010 PMid:10718103
Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999; 44:835-838. https://doi.org/10.1093/jac/44.6.835 PMid:10590288
Yoshida K, Okimoto N, Kishimoto M, et al. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. J Infect Chemother. 2011; 17:678-685. https://doi.org/10.1007/s10156-011-0282-6 PMid:21847518
Miravittles M, Llor C, Naberan K, et al. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Invest. 2004; 24(2):63-72. https://doi.org/10.2165/00044011-200424020-00001
World Health Organization. Guidelines for controlling and monitoring the tobbaco epidemic. Geneva: WHO, 1998.
Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000; 117:1638-1645. https://doi.org/10.1378/chest.117.6.1638 PMid:10858396
Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S. Smoking status in exposed and unexposed workers. Mak med pregled. 2006; 60(68):128.
Minov J, Karadzinska-Bislimovska J, Vasilevska K, et al. Exposure to environmental tobacco smoke in the workplace in Macedonia: Where are we now? Arh Hig Rada Toksikol. 2008; 59:103-109. https://doi.org/10.2478/10004-1254-59-2008-1870 PMid:18573747
Minov J, Karadzinska-Bislimovska J, Petrova T, Vasilevska K, Stoleski S, Mijakoski D, Risteska-Kuc S. Efficacy and tolerability of eight antimicrobial regimens in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease. Open Access Maced J Med Sci 2014; 2(3):519-524. https://doi.org/10.3889/oamjms.2014.093
Acevski S, Minov J, Sterjev Z, et al. Cost effectiveness analysis of antibiotic regimens used in outpatient treatment of exacerbations of chronic obstructive pulmonary disease (COPD). Adv Pharmacoepidemiol Drug Saf. 2016; 5:5.
Kai-Xiong L, Bing X, Wang J, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis. 2014; 6(3):221-229.
Juan Pastor A, Llopia Roca F, Masuet Aumatell C, et al. COPD exacerbations treated with oral moxifloxacin versus other intravenous antibiotics in a short-stay emergency outpatient clinic: a comparative study. Emergencias. 2007; 19:65-69.
Chuchalin A, Zakharova M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). BMC pulmonary Medicine. 2013; 13:5. https://doi.org/10.1186/1471-2466-13-5 PMid:23343427 PMCid:PMC3560260
Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulonic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012; 40:17-27. https://doi.org/10.1183/09031936.00090311 PMid:22135277 PMCid:PMC3393767
Manalan K, Rashid T, Singanayagam A. Antibiotic treatment in exacerbations of chronic obstructive pulmonary disease: recent trial results. Clin Invest. 2015; 5(2):189-204. https://doi.org/10.4155/cli.14.113
Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect. 2006; 12(3):42-54. https://doi.org/10.1111/j.1469-0691.2006.01396.x PMid:16669928
Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbations in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-1138. https://doi.org/10.1056/NEJMoa0909883 PMid:20843247
Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000; 117:1345-1352. https://doi.org/10.1378/chest.117.5.1345 PMid:10807821
Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004; 125:953-964. https://doi.org/10.1378/chest.125.3.953 PMid:15006954
Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis. 2007; 2(3):191-204. PMid:18229559 PMCid:PMC2695197
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Jordan Minov, Sasho Stoleski, Tatjana Petrova, Kristin Vasilevska, Dragan Mijakoski, Jovanka Bislimovska-Karadzhinska
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
